An interventional study of endoscopic approch in Nasal Cavity and Paranasal Sinus Cancer, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Year to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Assiut University · Not applicable, Interventional, and Treatment
Research outcome measures:
Primary (main):
To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas
Secondary (subsidiary):
Sinonasal tumors are a heterogeneous group of neoplasms arising from the nasal cavity and paranasal sinuses, representing a rare subset of head and neck tumors. Tumors arising from the sinonasal cavity can be subdivided into benign and malignant characters .Sinonasal malignancy are rare, representing \<1% of all malignancies and \<5% of head and neck cancers.Benign sinonasal tumors are more common than malignant lesions and include inverted papilloma, hemangioma, osteoma, juvenile nasopharyngeal angiofibroma, and various fibrous and glandular neoplasms.(1)The sinonasal cavity includes the epithelial, mesenchymal, salivary gland, cartilaginous and osseous proponents, and as such, it may lead to various original malignancies including the squamous cell carcinoma (most common) and the others (adenocarcinoma, adenoid cystic carcinoma, sarcoma, olfactory neuroblastoma,).(2) Surgical resection is often the first step of the therapeutic strategy in treatment of sinonasal tumors, possibly combined with adjuvant therapies .Tumors at pterygopalatine and infratemporal fossae,sphenoid and maxillary sinus poses challenges to surgeons for their deep location and intimate relationship with highly functional neurovascular and osteo-muscular structures .(3)Tumors in these challenging regions were managed via invasive open surgical resection ,these interventions are frequently morbid, resulting in profound neurological and functional sequelae that adversely impact the patient's clinical outcomes.(4) Endoscopic endonasal surgery become a standard approach in the management of many benign and selected malignant sinonasal tumors .It is as a minimally invasive surgical alternative, facilitating access to difficult locations with preserving the osteo-ligamental and muscular structures with no visible scars, optimal cosmetic outcome, and consequently limited risk of permanent neurological or functional deficits.(5)
55 studies on the registry are indexed under Paranasal Sinus Neoplasms; 6 are open to participants now.
This study's planned enrollment of 25 is below the median of 32 across 48 interventional studies indexed under Paranasal Sinus Neoplasms.
Browse Paranasal Sinus Neoplasms studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
-Patients with sinonasal and nasopharyngeal tumors
Exclusion Criteria:
Procedure: endoscopic approch
mangment of endoscopic approch in sinonasal tumors excision
Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations
To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas
Time frame: 4 years
percentage of complete resection post operative
complete resection of tumer by endoscopic approch
Time frame: 2 years
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University